One Health Company Secures $10M In New Financing

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

October 29, 2020

One Health Company is a bio company bridging the gap between canine and human cancer therapeutics. Today they announced that have secured $10M in new financing from Polaris Partners and Borealis Ventures, with participation from existing investors Andreessen Horowitz, Lerer Hippeau, Y-Combinator, and Tau Ventures.

One Health Company highlights the new financing will enable the company to accelerate the expansion of its flagship product, FidoCure®, in a time where pets are increasingly family members and demand for pet care solutions has boomed.

It’s a little known fact: the cancer treatments that help humans can also help dogs. That’s because humans and dogs co-evolved, and their cancers develop and progress in strikingly similar ways. Moreover, cancer is sadly the number one disease killer of dogs. One Health Company is the first company to bridge the gap by making precision medicine accessible for dogs. As One Health Company’s footprint grows with FidoCure®, so does the company’s ability to leverage its extensive dataset to benefit the other side of the leash- human cancer treatment.

“Cancer care for dogs has not changed much in the last 30 years, but human cancer care has tremendously advanced, especially in the field of precision medicine,” said Christina Lopes, co-founder, and CEO of One Health. “Using the same advanced cancer diagnostics and precision medicine that are currently on the market and approved by the FDA for people, we are bringing cancer care for dogs. And when we open access to precision cancer treatments for our furry friends, we build data that helps advance human oncology research and treatment.”

More than 90 million dogs are living in U.S. households, and an estimated one out of four of them will develop cancer at some point in their lives. According to Care Credit, the average cost today for cancer treatment for dogs is between $6,000 to $10,000[1], which makes it inaccessible to many. Accessibility is becoming increasingly critical, as pet ownership and spending is on the rise in 2020[2] now that social distancing is the norm and families try to combat loneliness and isolation by adding furry best friends to their families.

FidoCure® allows pet parents and veterinarians to access the first human-grade precision medicine platform for dogs at a lower price. Currently available in all US states at more than 200 participating veterinarians, FidoCure® already grew its’ patient footprint to over 1,000 dogs enrolled. Over 25% of the practicing veterinary oncologists in the US have adopted FidoCure®.

How Fidocure works:

  • Genetic Testing: Fidocure uses next-generation sequencing at a Clia certified lab (human grade) to understand the exact genetic mutation that may be driving a dog’s cancer.
  • Precision Medicine Report: Clear recommendations to help understand what is driving a dog’s cancer and the therapeutic implications of these mutations.
  • Treatment: Genetic sequencing results are used to enable access to individualized, targeted treatment leveraging the latest science available in human and canine oncology.

Veterinarians interested in Fidocure can contact the company visit here.





Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.